5-Amino-1MQ 50mg/capsule, 60 caps
5-Amino-1MQ 50mg/capsule, 60 caps
Currently unavailable
NovaMeds
4′-DMA-7,8-DHF, also designated Eutropoflavin, is a synthetic flavonoid derivative studied for its potential to modulate TrkB receptor activity.
Presentation: 4’-DMA-7,8-DHF ( Eutropoflavin ) 10mg / 60 capsule.
Illustrative packaging generated with AI.
Not for human or veterinary use.
4′-DMA-7,8-DHF, also designated Eutropoflavin, is a synthetic flavonoid derivative studied for its potential to modulate TrkB receptor activity. Research interest centers on its role in peptide-receptor signalling cascades, neurotrophic factor analogue research, and downstream kinase pathway investigation in controlled laboratory environments.
Research applications include TrkB receptor pharmacology, neurotrophic signalling pathway studies, and comparative flavonoid receptor-modulator research.
| Chemical Formula | C17H15NO4 |
|---|---|
| Synonyms | Eutropoflavin, 4′-Dimethylamino-7,8-dihydroxyflavone, 2-(4-(Dimethylamino)phenyl)-7,8-dihydroxy-4H-chromen-4-one, 4′-DMA-7,8-DHF |
| Molar Mass | 297.30 g/mol |
| CAS Number | 1205548-04-4 |
| PubChem CID | 44610701 |
| Total Compound Content | 600mg (10mg per capsule) |
| Shelf Life | 36 months |
4′-DMA-7,8-Dihydroxyflavone (Eutropoflavin) is studied as a synthetic flavonoid derivative with proposed TrkB receptor modulating activity. Research models examine its proposed role in peptide-receptor signalling cascades, drawing comparison to endogenous neurotrophic factor signalling pathways, and its downstream effects on kinase cascades implicated in receptor-mediated cellular signalling. As a structurally modified flavonoid, comparative research has examined how its substitution pattern relative to the parent flavone scaffold may influence receptor interaction characteristics relative to other flavonoid-class research compounds. Independently third-party HPLC-tested; COA available per batch.
Cell lines expressing TrkB receptor constructs are used in receptor engagement and downstream signalling assays, typically measuring receptor dimerization, autophosphorylation status, and activation of downstream kinase cascades following compound exposure. Comparative assays against established neurotrophic factor reference standards allow researchers to characterise the relative signalling profile produced by 4′-DMA-7,8-DHF exposure within the TrkB receptor research framework.
As a structurally modified flavonoid derivative, 4′-DMA-7,8-DHF is studied within structure-activity relationship research examining how specific substitutions on the flavone scaffold influence receptor interaction characteristics. Comparative research across structurally related flavonoid compounds allows investigation into which structural features are associated with TrkB pathway engagement, informing broader flavonoid-class receptor pharmacology research.
Western blot and phospho-specific antibody assays measuring activation status of downstream kinase intermediates in receptor signalling cascades are standard readouts used in cell-based models following compound exposure, allowing researchers to characterise which signalling branches are engaged. These molecular readouts are typically paired with functional cellular assays relevant to the specific research model under investigation.
Capsule excipients are not specified in the available product documentation.